Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000691744 | SCV000819534 | uncertain significance | Hereditary breast ovarian cancer syndrome | 2021-03-21 | criteria provided, single submitter | clinical testing | This variant has been reported not to substantially affect BRCA1 protein function (PMID: 30209399). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt BRCA1 protein function. This variant has not been reported in the literature in individuals with BRCA1-related conditions. ClinVar contains an entry for this variant (Variation ID: 570792). This variant is not present in population databases (ExAC no frequency). This sequence change replaces glutamic acid with glutamine at codon 1635 of the BRCA1 protein (p.Glu1635Gln). The glutamic acid residue is moderately conserved and there is a small physicochemical difference between glutamic acid and glutamine. |
Brotman Baty Institute, |
RCV001077822 | SCV001243814 | not provided | Breast-ovarian cancer, familial, susceptibility to, 1 | no assertion provided | in vitro |